ReviewTranslational andrology and urology2017
The dangers of sexual enhancement supplements and counterfeit drugs to "treat" erectile dysfunction.
Review in Translational andrology and urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An Analysis of Popular Online Erectile Dysfunction Supplements.The journal of sexual medicine · 2019Pooled it
- Large language models for post-discharge follow-up in erectile dysfunction care: a narrative review.Translational andrology and urology · 2026Review
- Exploring Patient Pathways and Care Situations in Men With Erectile Dysfunction in Different PDE-5 Inhibitor Regulatory Settings.International journal of public health · 2025Article
- Radio frequency identification technology; A method of analysis of falsified pharmaceutical products: Literature review.SAGE open medicine · 2024Review
- Tackling Counterfeit Drugs: The Challenges and Possibilities.Pharmaceutical medicine · 2023Review
- A Devastating Tear: Atypical Presentation of Aortic Dissection Discovered on Echocardiography.Cureus · 2023Article
- Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts.Frontiers in pharmacology · 2023Article
- Orodispersible Film (ODF) Platform Based on Maltodextrin for Therapeutical Applications.Pharmaceutics · 2022Review
- Survey on Sildenafil, Tadalafil, and Vardenafil Concentrations in Food Supplements for Erectile Dysfunction.International journal of analytical chemistry · 2022Article
- Facing Counterfeit Medications in Sexual Medicine. A Systematic Scoping Review on Social Strategies and Technological Solutions.Sexual medicine · 2021Article
- The Economics of Viagra Revisited: The Price Is Right.Urology · 2021Article
- Contribution of sewage to occurrence of phosphodiesterase-5 inhibitors in natural water.Scientific reports · 2021Article
- "Doc, if it were you, what would you do?": a survey of Men's Health specialists' personal preferences regarding treatment modalities.International journal of impotence research · 2021Article
- Efficacy and Safety of Common Ingredients in Aphrodisiacs Used for Erectile Dysfunction: A Review.Sexual medicine reviews · 2020Review
- Article
- A review of the evolving landscape between the consumer Internet and men's health.Translational andrology and urology · 2020Review
- EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil.Sexual medicine · 2018Article
- Hospital Audit as a Useful Tool in the Process of Introducing Falsified Medicines Directive (FMD) into Hospital Pharmacy Settings-A Pilot Study.Pharmacy (Basel, Switzerland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Counterfeit phosphodiesterase-5 inhibitors (PDE-5i) are an increasing problem. Already in widespread use, the market for PDE-5i is steadily growing as the population ages. Counterfeiters are taking advantage of this growing market by developing illicit and counterfeit PDE-5i products. Many factors are contributing to the rapid growth of the illicit market, such as the low risk of prosecution, potentially high financial reward, and ease of distribution via Internet pharmacies. Consumers of illicit PDE-5i often do not realize they are using counterfeit products and placing themselves at an unnecessary health risk. Others seek to bypass the legitimate healthcare system due to either embarrassment of the underlying condition or desire for cheaper alternatives. However, taking illicit PDE-5i may harm consumers directly, as many illicit products contain detrimental contaminants and inaccurate amounts of the active ingredient without the appropriate warnings. Bypassing the legitimate healthcare system also endangers consumers indirectly, as erectile dysfunction (ED) is often associated with other medical comorbidities that patients should be screened for. Furthermore, PDE-5i can have potentially dangerous interactions with other pharmaceuticals that are rarely warned against with counterfeit PDE-5i. This communication reviews the literature regarding counterfeit PDE-5i, and summarizes both the scope and dangers of the illicit PDE-5i market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.